Lame Tablets 10mg 2x15s

What it is used for: Hypertension.

Indications as listed by the manufacturer: Lisinopril is indicated for: Hypertension : The treatment of hypertension. Heart failure : The treatment of symptomatic heart failure. Acute myocardial infarction : Short-term (6 weeks) treatment of haemodynamically stable patients within 24 hours of an acute myocardial infarction. Renal complications of diabetes mellitus : Treatment of renal disease in hypertensive patients with type 2 diabetes mellitus and incipient nephropathy.

How it works: Lisinopril is a peptidyl dipeptidase inhibitor. It inhibits the angiotensin converting enzyme (ACE) that catalyses the conversion of angiotensin I to the vasoconstrictor peptide, angiotensin II. Whilst mechanism through which lisinopril lowers blood pressure is believed to be primarily suppression of the renin-angiotensin-aldosterone system. Lisinopril is antihypertensive even in patients with low-renin hypertension.

Active ingredient: Lisinopril.

Reported side effects: Common: Dizziness, headache, orthostatic effects (including hypotension), cough, diarrhea, nausea, vomiting. Uncommon: Mood alterations, paraesthesia, vertigo, taste disturbance, sleep disturbances, myocardial infarction or cerebrovascular accident, possibly secondary to excessive hypotension in high risk patients, palpitations, tachycardia. Raynaud's phenomenon, rhinitis, abdominal pain and indigestion, rash, pruritus, impotence, fatigue, asthenia, increase in blood urea, increase in serum creatinine, increasein liver enzymes, hyperkalaemia. Rare: Decrease in hemoglobin, decrease in hematocrit, mental confusion, dry mouth, hypersensitivity/angioneurotic edema: angioneurotic edema of the face, extremities, lips, tongue, glottis, and/or larynx, urticaria, alopecia, psoriasis, uraemia, acute renal failure. Very rare: Bone marrow depression, anaemia, thrombocytopenia, leucopenia, neutropenia, agranulocytosis, haemolytic anaemia, lymphadenopathy, autoimmune disease, hypoglycemia, bronchospasm, sinusitis, allergic alveolitis/eosinophilic pneumonia, pancreatitis, intestinal angioedema, hepatitis - either hepatocellular or cholestatic, jaundice and hepatic failure, diaphoresis, pemphigus, toxic epidermal necrolysis, Stevens-Johnson Syndrome, erythema multiforme, oliguria/anuria, gynaecomastia, increase in serum bilirubin, hyponatremia.

Known drug interactions: Diuretics , Potassium supplements, potassium-sparing diuretics (e.g. spironolactone, triamterene or amiloride) or potassium-containing salt substitutes, Lithium , NSAIDs and ACE inhibitors , glyceryl trinitrate and other nitrates , tricyclic antidepressants and antipsychotics , Sympathomimetics , antidiabetic medicines (insulins, oral hypoglycemic agents ) .

Hypertension : In patients with hypertension the usual recommended starting dose of Lisinopril is 10mg . The usual effective maintenance dosage is 20mg administered in a single dailydose. In general if the desired therapeutic effect cannot be achieved in a period of 2 to 4 weeks on a certain dose level, the dose can be further increased up to 80mg daily, if necessary. Acute myocardial infarction : Starting dose Treatment with lisinopril may be started within 24 hours of the onset of symptoms in an initial dose of 5mg once daily for two days, and then increased to 10mgonce daily. An initial dose of 2.5mg once daily is recommended for patients with a low systolic blood pressure. Maintenance dose : The maintenance dose is 10mg once daily. Renal complications of diabetes mellitus : The initial dose is 2.5mg once daily. In normotensive type 1 diabetics the maintenance dose is 10mg daily, increased to 20mg daily. The dose should be individualised according to patient profile and blood pressure response.

Follow your doctor’s instructions. The dosage above is the usual range — your prescription takes precedence over it.

Active ingredient: Lisinopril. Labelled strength: 10mg.

Store this medicine at room temperature, away from direct light and heat.

Manufactured by Lame Healthcare (Pvt) Ltd.. Country of origin: Pakistan.